LSZ-102 Uses, Dosage, Side Effects and more
LSZ-102 is under investigation in clinical trial NCT02734615 (Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers).
| Trade Name | LSZ-102 |
| Generic | LSZ-102 |
| Type | |
| Formula | C25H17F3O4S |
| Weight | Average: 470.46 Monoisotopic: 470.07996469 |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
